股腘动脉严重肢体缺血球囊与支架对比研究-3(BASIL-3):随机对照试验研究方案
BASIL-3是一项由英国国家卫生研究院卫生技术评估项目资助的多中心随机对照试验,比较普通球囊血管成形术(必要时补救性裸金属支架)、药物涂层球囊血管成形术(必要时补救性裸金属支架)和药物洗脱支架直接支架植入术治疗股腘动脉病变所致严重肢体缺血的临床与成本效果。主要临床结局为无截肢生存,即至索引肢体踝上大截肢或任何原因死亡的时间;经济学主要结局为每质量调整生命年成本。计划样本量861例(每组287例),招募期3年,随访2至5年。
要点
- 比较普通球囊、药物涂层球囊和药物洗脱支架治疗股腘动脉严重肢体缺血的临床与成本效果。
- 主要临床结局为无截肢生存(至索引肢体踝上大截肢或任何原因死亡的时间)。
- 计划样本量861例(每组287例),招募3年,随访2至5年。
核心结论
- BASIL-3为实用性随机对照试验,旨在反映英国当前临床实践,其结果将为英国国家卫生研究院是否资助药物涂层球囊和药物洗脱支架用于股腘动脉病变所致严重肢体缺血提供决策依据。
研究设计与样本
- 英国国家卫生研究院卫生技术评估项目资助的多中心随机对照试验,比较三种血管内血运重建策略治疗股腘动脉病变所致严重肢体缺血。
- 计划样本量861例,每组287例,招募期3年,随访2至5年。
- 合并多节段病变的患者可在随机分配的股腘动脉干预同时接受主髂动脉和/或膝下动脉治疗。
主要发现
- 主要临床结局为无截肢生存,定义为至索引肢体踝上大截肢或任何原因死亡的时间。
- 经济学分析主要结局为每质量调整生命年成本。
- 次要结局包括总生存、主要不良肢体事件、主要不良心脏事件、缺血性疼痛缓解、组织缺损愈合和生活质量。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Severe limb ischaemia (SLI) is defined as the presence of rest pain and/or tissue loss secondary to lower extremity atherosclerotic peripheral arterial disease. The superficial femoral and popliteal arteries are the most commonly diseased vessels in such patients and are being increasingly treated using endovascular revascularisation techniques. However, it is currently unknown whether drug-eluting stents and drug-coated balloons confer additional clinical benefits over more established techniques using plain balloons and bare metal stents, or whether they represent a cost-effective use of NHS resources. METHODS: The BASIL-3 trial is a UK National Institute for Health Research, Health Technology Assessment Programme-funded, multicentre, randomised controlled trial (RCT) comparing the clinical and cost-effectiveness of plain balloon angioplasty with or without bail-out bare metal stenting, drug-coated balloon angioplasty with or without bail-out bare metal stenting, and primary stenting with drug-eluting stents for SLI secondary to femoro-popliteal disease. Patients with 'multilevel' disease may receive aorto-iliac and/or infrapopliteal treatments concurrently with their randomised femoro-popliteal intervention. The primary clinical outcome is amputation-free survival defined as the time to major (above the ankle) amputation of the index limb or death from any cause. The primary outcome for the economic analysis is cost per quality-adjusted life year. Secondary outcome measures include overall survival, major adverse limb events, major adverse cardiac events, relief of ischaemic pain, healing of tissue loss, and quality of life. The required sample size has been calculated at 861 participants (287 on each arm). These patients will be recruited over 3 years and followed-up for between 2 and 5 years. DISCUSSION: BASIL-3 is a pragmatic RCT designed to reflect current UK clinical practice. The results will inform decision-making regarding the appropriateness of funding the use of drug-coated balloons and drug-eluting stents, by the NHS, for the management of SLI due to femoro-popliteal disease. TRIAL REGISTRATION: ISRCTN Registry, identifier: ISRCTN14469736 . Registered on 22 October 2015.
引用
- Hunt BD, Popplewell MA, Davies H, et al. BAlloon versus Stenting in severe Ischaemia of the Leg-3 (BASIL-3): study protocol for a randomised controlled trial. Trials. 2017. PMID: 28526046. doi:10.1186/s13063-017-1968-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。